CIK 0001727196 · Non-accelerated filer
Scholar Rock Holding Corp
Sign in to watch- Ticker
- SRRK
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 823750435
- Phone
- 857-259-3860
- Business address
- 301 BINNEY STREET, 3RD FLOOR, CAMBRIDGE, MA, 02142
- Open-market buys, last 90 days
- $11,999,922
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$11,999,922. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-02-09 | Hallal David Chief Executive Officer | Grant or award | +128,004 | 1,669,649 | ||
| 2026-02-09 | Woods Keith Chief Operating Officer | Grant or award | +47,021 | 630,275 | ||
| 2026-01-22 | Qatanani Mo CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −2,119 | $45.87 | $97K | 98,439 |
| 2026-01-22 | Qatanani Mo CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −12,779 | $46.85 | $599K | 85,660 |
| 2026-01-16 | Qatanani Mo CHIEF SCIENTIFIC OFFICER | Sale | −8,406 | $44.48 | $374K | 100,558 |
| 2026-01-16 | Parlavecchio Caryn CHRO | Sale | −6,600 | $44.48 | $294K | 148,864 |
| 2026-01-16 | Ho Junlin GENERAL COUNSEL | Sale | −8,016 | $44.48 | $357K | 214,553 |
| 2026-01-16 | Marantz Jing L. CHIEF MEDICAL OFFICER | Sale | −5,798 | $44.48 | $258K | 95,687 |
| 2026-01-14 | Qatanani Mo CHIEF SCIENTIFIC OFFICER | Option exercise 10b5-1 | +1,407 | $18.08 | $25K | 110,371 |
| 2026-01-14 | Qatanani Mo CHIEF SCIENTIFIC OFFICER | Option exercise 10b5-1 | +321 | $7.62 | $2K | 110,692 |
| 2026-01-14 | Qatanani Mo CHIEF SCIENTIFIC OFFICER | Option exercise 10b5-1 | +2,813 | $10.00 | $28K | 113,505 |
| 2026-01-14 | Qatanani Mo CHIEF SCIENTIFIC OFFICER | Option exercise 10b5-1 | +5,893 | $15.75 | $93K | 119,398 |
| 2026-01-14 | Qatanani Mo CHIEF SCIENTIFIC OFFICER | Option exercise 10b5-1 | +2,678 | $35.15 | $94K | 122,076 |
| 2026-01-14 | Qatanani Mo CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −13,112 | $45.20 | $593K | 108,964 |
| 2026-01-14 | Qatanani Mo CHIEF SCIENTIFIC OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −1,407 | 0 | ||
| 2026-01-14 | Qatanani Mo CHIEF SCIENTIFIC OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −321 | 961 | ||
| 2026-01-14 | Qatanani Mo CHIEF SCIENTIFIC OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −2,813 | 11,250 | ||
| 2026-01-14 | Qatanani Mo CHIEF SCIENTIFIC OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −5,893 | 47,143 | ||
| 2026-01-14 | Qatanani Mo CHIEF SCIENTIFIC OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −2,678 | 32,142 | ||
| 2026-01-13 | Sinha Vikas Chief Financial Officer | Sale | −16,755 | $42.70 | $715K | 583,245 |
Page 4 of 12 · 227 trades